Clonorchiasis (Clonorchis sinensis infection)
Conditions
Interventions
Albendazole group:None
Praziquantel group:None
Sponsors
The People’s Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with clonorchiasis by detecting Clonorchis sinensis eggs or worms in fecal examinations or biliary drainage fluid; 2. Patients who received standard treatment with albendazole and praziquantel at the research center from January 2023 to March 2025; 3. Patients with complete medical records, including diagnostic evidence, medication regimens, post-treatment egg test results, and safety records.
Exclusion criteria
Exclusion criteria: 1. Patients with incomplete data records, for whom the efficacy/safety indicators cannot be clearly identified; 2. Patients co-infected with other parasites; 3. Patients who changed medications, discontinued treatment, or failed to complete follow-up during the treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Egg negative conversion rate; | — |
Countries
China
Contacts
Public ContactZhang Li
The People’s Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed